Hims & Hers Health is trading at €25.36, a change of -3.21%; no confirmed company-specific catalyst directly explains the decline.
- On October 21, Hims announced new injectable and oral testosterone therapies, but available reporting does not link the launch to the drop.
- Securities-class-action notices also appeared October 21; they concern allegations and a July 29 share-price fall, not a demonstrated cause of this move.
- Futures pointed lower, but this alone does not establish why the shares fell.